pharmaceuticals-and-healthcare

United States Biologics and Biosimilars Market Report 2017


Published On : May 2017

Category : Pharmaceutical

No. of Pages : 117 pages

  • $3800
  • $7600

Please click below to avail discount on this report

In this report, the United States Biologics and Biosimilars market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
The West
Southwest
The Middle Atlantic
New England
The South
The Midwest
with sales (volume), revenue (value), market share and growth rate of Biologics and Biosimilars in these regions, from 2012 to 2022 (forecast).

United States Biologics and Biosimilars market competition by top manufacturers/players, with Biologics and Biosimilars sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
Pfizer
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Novo Nordisk
Novartis
Merck
Lilly
3sbio
Changchun High Tech
CP Guojian Pharmacy
Biotech Pharma
Gelgen Biopharma
Sandoz
Teva
Hospira
Mylan
3sbio
Changchun High Tech
CP Guojian Pharmacy
Biotech Pharma
Gelgen Biopharma

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
Antibiotic
Enzyme
Hormone
Non-Patented Biological Reagents
Other
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Biologics and Biosimilars for each application, including
Tumor
Diabetes
Cardiovascular
Hemophilia
Other

If you have any special requirements, please let us know and we will offer you the report as you want.

In the recent times, the global market for United states biologics and biosimilars market report 2017 has surfaced as one of the most promising markets in the pharmaceutical industry, thanks to the significant rise in research and development activities by leading vendors of United states biologics and biosimilars market report 2017 across the world. Manufacturers have turned to technological innovations and data-driven customization to satisfy the augmenting consumer demand for efficiency and more accuracy in results, leading to an increased usage of technology in the United states biologics and biosimilars market report 2017 production processes, which is also reflecting positively on the growth of this market.

The research report on the United states biologics and biosimilars market report 2017 is an analytical study which comprehensively analyzes the competitive framework of this market. Using a number of effective assessment tools, such as porter’s five forces and value chain analysis, it performs in-depth analyses of the production and supply as well as the demand and sales of United states biologics and biosimilars market report 2017 and provides deep insights into the future prospects of this market.

The study begins with a detailed overview of the market for United states biologics and biosimilars market report 2017, including the definition, classification, and industry chain structure of United states biologics and biosimilars market report 2017, and move forward to cover every aspect of this market, counting several criteria based on which the market is classified. Focusing specifically on the key trends, it further evaluates the overall performance of this market during the assessment period. With chemical industry undergoing a phase of technological disruption, innovations in products are likely to shape the future of the United states biologics and biosimilars market report 2017.

In this research report, apart from the trends, the driving forces, restraints, and opportunities have also been taken into consideration to determine the market’s future. Further, it offers an estimation of the market size in terms of value (US$) and in volume (kilo tons) and talks about the key segments and the geographical subdivisions of the market for United states biologics and biosimilars market report 2017 in details. It provides in-depth information on the development trends and the policies and regulations, concerning United states biologics and biosimilars market report 2017, implemented in each of the geographical segments. The predominant applications of the United states biologics and biosimilars market report 2017 have also been discussed at length in this research study.

With all these analyses and information, this report can act as a valuable guide to readers looking to gain a clear understanding of all the factors that are influencing the market for United states biologics and biosimilars market report 2017 at present and are projected to remain doing so over the forecast period. Readers will also benefit significantly from the important information regarding this market, provided in the forms of figures and tables in the research report.

Additionally, the information on the latest developments in this market, both, at the global as well as regional level, is expected to enhance the decision-making capability of the reader. Up-to-date information on various specifications, buyer analysis, their purchasing volume, prices, and price analysis, and deep insights on the leading suppliers have also been provided in this study for the readers.

At last, the report offers key industry recommendations to companies looking to venture into the United states biologics and biosimilars market report 2017 from both the perspectives, i.e. demand and supply. The main objective of this research study is to assist stakeholders operating in this market in creating efficient counter strategies to gain an edge over their competitors.

List of Tables and Figures

Figure Product Picture of Biologics and Biosimilars
Figure United States Biologics and Biosimilars Market Size (K MT) by Type (2012-2022)
Figure United States Biologics and Biosimilars Sales Volume Market Share by Type (Product Category) in 2016
Figure Antibiotic Product Picture
Figure Enzyme Product Picture
Figure Hormone Product Picture
Figure Non-Patented Biological Reagents Product Picture
Figure Other Product Picture
Figure United States Biologics and Biosimilars Market Size (K MT) by Application (2012-2022)
Figure United States Sales Market Share of Biologics and Biosimilars by Application in 2016
Figure Tumor Examples
Figure Diabetes Examples
Figure Cardiovascular Examples
Figure Hemophilia Examples
Figure Other Examples
Figure United States Biologics and Biosimilars Market Size (Million USD) by Region (2012-2022)
Figure The West Biologics and Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Biologics and Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Biologics and Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Biologics and Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Biologics and Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Biologics and Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Biologics and Biosimilars Sales (K MT) and Growth Rate (2012-2022)
Figure United States Biologics and Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Biologics and Biosimilars Market Major Players Product Sales Volume (K MT) (2012-2017)
Table United States Biologics and Biosimilars Sales (K MT) of Key Players/Suppliers (2012-2017)
Table United States Biologics and Biosimilars Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Biologics and Biosimilars Sales Share by Players/Suppliers
Figure 2017 United States Biologics and Biosimilars Sales Share by Players/Suppliers
Figure United States Biologics and Biosimilars Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Biologics and Biosimilars Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Biologics and Biosimilars Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Biologics and Biosimilars Revenue Share by Players/Suppliers
Figure 2017 United States Biologics and Biosimilars Revenue Share by Players/Suppliers
Table United States Market Biologics and Biosimilars Average Price (USD/MT) of Key Players/Suppliers (2012-2017)
Figure United States Market Biologics and Biosimilars Average Price (USD/MT) of Key Players/Suppliers in 2016
Figure United States Biologics and Biosimilars Market Share of Top 3 Players/Suppliers
Figure United States Biologics and Biosimilars Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Biologics and Biosimilars Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Biologics and Biosimilars Product Category
Table United States Biologics and Biosimilars Sales (K MT) by Region (2012-2017)
Table United States Biologics and Biosimilars Sales Share by Region (2012-2017)
Figure United States Biologics and Biosimilars Sales Share by Region (2012-2017)
Figure United States Biologics and Biosimilars Sales Market Share by Region in 2016
Table United States Biologics and Biosimilars Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Biologics and Biosimilars Revenue Share by Region (2012-2017)
Figure United States Biologics and Biosimilars Revenue Market Share by Region (2012-2017)
Figure United States Biologics and Biosimilars Revenue Market Share by Region in 2016
Table United States Biologics and Biosimilars Price (USD/MT) by Region (2012-2017)
Table United States Biologics and Biosimilars Sales (K MT) by Type (2012-2017)
Table United States Biologics and Biosimilars Sales Share by Type (2012-2017)
Figure United States Biologics and Biosimilars Sales Share by Type (2012-2017)
Figure United States Biologics and Biosimilars Sales Market Share by Type in 2016
Table United States Biologics and Biosimilars Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Biologics and Biosimilars Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Biologics and Biosimilars by Type (2012-2017)
Figure Revenue Market Share of Biologics and Biosimilars by Type in 2016
Table United States Biologics and Biosimilars Price (USD/MT) by Types (2012-2017)
Figure United States Biologics and Biosimilars Sales Growth Rate by Type (2012-2017)
Table United States Biologics and Biosimilars Sales (K MT) by Application (2012-2017)
Table United States Biologics and Biosimilars Sales Market Share by Application (2012-2017)
Figure United States Biologics and Biosimilars Sales Market Share by Application (2012-2017)
Figure United States Biologics and Biosimilars Sales Market Share by Application in 2016
Table United States Biologics and Biosimilars Sales Growth Rate by Application (2012-2017)
Figure United States Biologics and Biosimilars Sales Growth Rate by Application (2012-2017)
Table Pfizer Basic Information List
Table Pfizer Biologics and Biosimilars Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Pfizer Biologics and Biosimilars Sales Growth Rate (2012-2017)
Figure Pfizer Biologics and Biosimilars Sales Market Share in United States (2012-2017)
Figure Pfizer Biologics and Biosimilars Revenue Market Share in United States (2012-2017)
Table Roche Basic Information List
Table Roche Biologics and Biosimilars Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Roche Biologics and Biosimilars Sales Growth Rate (2012-2017)
Figure Roche Biologics and Biosimilars Sales Market Share in United States (2012-2017)
Figure Roche Biologics and Biosimilars Revenue Market Share in United States (2012-2017)
Table Amgen Basic Information List
Table Amgen Biologics and Biosimilars Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Amgen Biologics and Biosimilars Sales Growth Rate (2012-2017)
Figure Amgen Biologics and Biosimilars Sales Market Share in United States (2012-2017)
Figure Amgen Biologics and Biosimilars Revenue Market Share in United States (2012-2017)
Table AbbVie Basic Information List
Table AbbVie Biologics and Biosimilars Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure AbbVie Biologics and Biosimilars Sales Growth Rate (2012-2017)
Figure AbbVie Biologics and Biosimilars Sales Market Share in United States (2012-2017)
Figure AbbVie Biologics and Biosimilars Revenue Market Share in United States (2012-2017)
Table Sanofi Basic Information List
Table Sanofi Biologics and Biosimilars Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Sanofi Biologics and Biosimilars Sales Growth Rate (2012-2017)
Figure Sanofi Biologics and Biosimilars Sales Market Share in United States (2012-2017)
Figure Sanofi Biologics and Biosimilars Revenue Market Share in United States (2012-2017)
Table Johnson & Johnson Basic Information List
Table Johnson & Johnson Biologics and Biosimilars Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Johnson & Johnson Biologics and Biosimilars Sales Growth Rate (2012-2017)
Figure Johnson & Johnson Biologics and Biosimilars Sales Market Share in United States (2012-2017)
Figure Johnson & Johnson Biologics and Biosimilars Revenue Market Share in United States (2012-2017)
Table Novo Nordisk Basic Information List
Table Novo Nordisk Biologics and Biosimilars Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Novo Nordisk Biologics and Biosimilars Sales Growth Rate (2012-2017)
Figure Novo Nordisk Biologics and Biosimilars Sales Market Share in United States (2012-2017)
Figure Novo Nordisk Biologics and Biosimilars Revenue Market Share in United States (2012-2017)
Table Novartis Basic Information List
Table Novartis Biologics and Biosimilars Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Novartis Biologics and Biosimilars Sales Growth Rate (2012-2017)
Figure Novartis Biologics and Biosimilars Sales Market Share in United States (2012-2017)
Figure Novartis Biologics and Biosimilars Revenue Market Share in United States (2012-2017)
Table Merck Basic Information List
Table Merck Biologics and Biosimilars Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Merck Biologics and Biosimilars Sales Growth Rate (2012-2017)
Figure Merck Biologics and Biosimilars Sales Market Share in United States (2012-2017)
Figure Merck Biologics and Biosimilars Revenue Market Share in United States (2012-2017)
Table Lilly Basic Information List
Table Lilly Biologics and Biosimilars Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Lilly Biologics and Biosimilars Sales Growth Rate (2012-2017)
Figure Lilly Biologics and Biosimilars Sales Market Share in United States (2012-2017)
Figure Lilly Biologics and Biosimilars Revenue Market Share in United States (2012-2017)
Table 3sbio Basic Information List
Table Changchun High Tech Basic Information List
Table CP Guojian Pharmacy Basic Information List
Table Biotech Pharma Basic Information List
Table Gelgen Biopharma Basic Information List
Table Sandoz Basic Information List
Table Teva Basic Information List
Table Hospira Basic Information List
Table Mylan Basic Information List
Table 3sbio Basic Information List
Table Changchun High Tech Basic Information List
Table CP Guojian Pharmacy Basic Information List
Table Biotech Pharma Basic Information List
Table Gelgen Biopharma Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Biologics and Biosimilars
Figure Manufacturing Process Analysis of Biologics and Biosimilars
Figure Biologics and Biosimilars Industrial Chain Analysis
Table Raw Materials Sources of Biologics and Biosimilars Major Players/Suppliers in 2016
Table Major Buyers of Biologics and Biosimilars
Table Distributors/Traders List
Figure United States Biologics and Biosimilars Sales Volume (K MT) and Growth Rate Forecast (2017-2022)
Figure United States Biologics and Biosimilars Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Biologics and Biosimilars Price (USD/MT) Trend Forecast (2017-2022)
Table United States Biologics and Biosimilars Sales Volume (K MT) Forecast by Type (2017-2022)
Figure United States Biologics and Biosimilars Sales Volume (K MT) Forecast by Type (2017-2022)
Figure United States Biologics and Biosimilars Sales Volume (K MT) Forecast by Type in 2022
Table United States Biologics and Biosimilars Sales Volume (K MT) Forecast by Application (2017-2022)
Figure United States Biologics and Biosimilars Sales Volume (K MT) Forecast by Application (2017-2022)
Figure United States Biologics and Biosimilars Sales Volume (K MT) Forecast by Application in 2022
Table United States Biologics and Biosimilars Sales Volume (K MT) Forecast by Region (2017-2022)
Table United States Biologics and Biosimilars Sales Volume Share Forecast by Region (2017-2022)
Figure United States Biologics and Biosimilars Sales Volume Share Forecast by Region (2017-2022)
Figure United States Biologics and Biosimilars Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

Send an Enquiry

  • * :
  • * :
  • * :
  • * :
  • * :
  • :
  • * :
  • * indicates required field.

LATEST NEWS


Back To Top